A trial looking at different treatments for neuroblastoma which has come back after initial therapy

This trial is open to children and young people aged 1 year and older who have high-risk neuroblastoma that has come back (relapsed) or progressed after previous treatment. The cancer must be visible on medical imaging, such as an MIBG scan or MRI scan. Children who only have cancer cells in their bone marrow without any visible tumour on scans cannot take part.

Participants need to be in reasonable general health to safely receive the study medicines. This means they should be able to sit up or be active for at least half of the day. Their main organs, including their kidneys, liver, and bone marrow, must be working well enough to cope with cancer treatment. A doctor will confirm these details with routine blood, urine, and imaging tests before anyone joins.

Taking part in BEACON2 involves receiving treatment in cycles that last three weeks each, for up to 12 cycles (about 9 months in total). Participants are assigned to a treatment arm that combines chemotherapy drugs (such as irinotecan and temozolomide) with targeted antibody therapies (such as dinutuximab beta or bevacizumab). Some medicines are given as a drip into a vein at the hospital, while others may be taken by mouth as liquids or capsules at home.

Families will need to make regular visits to the hospital for treatment days, check-ups, and monitoring. Doctors will carry out routine blood and urine tests, physical examinations, and regular scans (such as MIBG or CT scans) to check how the tumour is responding and watch for any side effects. After finishing the treatment cycles, your child will have regular follow-up visits so the care team can continue to monitor their health and recovery.